Medicine:Surfactant therapy
 | This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (October 2013) (Learn how and when to remove this template message) |
}}
| Surfactant therapy | |
|---|---|
| Other names | Surfactant application, Surfactant replacement |
| Specialty | neonatology |
Surfactant therapy is the medical administration of pulmonary surfactant that is derived from outside of the body. Pulmonary surfactant is a soap-like chemical synthesized by type II alveolar pneumocytes and is of various lipids (80% phospholipids, 5-10% cholesterol, and ~10% surfactant-associated proteins). This biological fluid reduces surface tension and lines the aqueous layer covering the alveolar surface of the lung. For more details, see Pulmonary surfactant.[1][2][3]
Surfactant therapy, or surfactant replacement therapy, is used in situations where there is not sufficient fluid covering the lung. The most common use is in premature neonates or babies born with respiratory distress syndrome. Conditions adult respiratory distress syndrome or Hyaline Membrane Disease are also sometimes treated with exogenously derived surfactant. One of the more common uses of surfactant therapy is to treat alveolar surfactant deficiency in premature newborns. Most commonly, treatment is composed of multiple doses of 100 mg/kg of exogenous surfactant.[2]
Types of Surfactants
LISA surfactant delivery in infants
The LISA (Less Invasive Surfactant Administration) method is much more effective in situations where the preterm infant is already breathing, and it has become a standard procedure in German hospitals.[4] Intubation via mechanical ventilation is less effective than the LISA method within the first 72 hours of birth.[5]
Respiratory Distress Syndrome
Exogenous surfactant replacement therapy is effective in reducing IRDS mortality and morbidity in preterm infants.[6][7][8][9]
Adult respiratory distress syndrome
Surfactant therapy is not used to treat adults with adult respiratory distress syndrome because the evidence regarding its effect on patient-important outcomes is inconsistent. As of 2019, there is no evidence showing that treatments with exogenous surfactants, statins, beta-blockers or N-acetylcysteine decreases early mortality, late all-cause mortality, duration of mechanical ventilation, or number of ventilator-free days.[10]
See also
- Respiratory care
- Nursing
- Neonatology
- Meconium aspiration syndrome
References
- ↑ Possmayer, Fred; Zuo, Yi Y.; Veldhuizen, Ruud A. W.; Petersen, Nils O. (2023-12-13). "Pulmonary Surfactant: A Mighty Thin Film" (in en). Chemical Reviews 123 (23): 13209–13290. doi:10.1021/acs.chemrev.3c00146. ISSN 0009-2665. PMID 37862151. https://pubs.acs.org/doi/10.1021/acs.chemrev.3c00146.
- ↑ 2.0 2.1 Robertson, Bengt; Halliday, Henry L. (1998-11-19). "Principles of surfactant replacement". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1408 (2): 346–361. doi:10.1016/S0925-4439(98)00080-5. ISSN 0925-4439. PMID 9813384. https://linkinghub.elsevier.com/retrieve/pii/S0925443998000805.
- ↑ Dhar, Dipak Kumar; Majumder, Nilratan; Paul, Debasish (2016). "Assessment of Knowledge and Practice of Mothers of Children under Five regarding Zinc Therapy in Childhood Diarrhea". International Journal of Advanced and Integrated Medical Sciences 1 (4): 169–172. doi:10.5005/jp-journals-10050-10055. ISSN 2456-2726. http://dx.doi.org/10.5005/jp-journals-10050-10055.
- ↑ Härtel, Christoph; Paul, Pia; Hanke, Kathrin; Humberg, Alexander; Kribs, Angela; Mehler, Katrin; Vochem, Matthias; Wieg, Christian et al. (29 May 2018). "Less invasive surfactant administration and complications of preterm birth". Scientific Reports 8 (1): 8333. doi:10.1038/s41598-018-26437-x. PMID 29844331. Bibcode: 2018NatSR...8.8333H.
- ↑ Lau, Christine S. M.; Chamberlain, Ronald S.; Sun, Shyan (24 March 2017). "Less Invasive Surfactant Administration Reduces the Need for Mechanical Ventilation in Preterm Infants". Global Pediatric Health 4: 2333794X1769668. doi:10.1177/2333794X17696683. PMID 28540346.
- ↑ Suresh, Gautham K; Soll, Roger F (21 April 2005). "Overview of Surfactant Replacement Trials". Journal of Perinatology 25 (S2): S40–S44. doi:10.1038/sj.jp.7211320. PMID 15861172.
- ↑ Fujiwara, Tetsuro; Chida, Shoichi; Watabe, Yoshitane; Maeta, Haruo; Morita, Tomoaki; Abe, Tadaaki (January 1980). "Artificial surfactant therapy in hyaline-membrane disease". The Lancet 315 (8159): 55–59. doi:10.1016/s0140-6736(80)90489-4. PMID 6101413.
- ↑ Liechty, Edward A.; Donovan, Edward; Purohit, Dilip; Gilhooly, Joseph; Feldman, Bernard; Noguchi, Akihiko; Denson, Susan E.; Sehgal, Sabitha S. et al. (1 July 1991). "Reduction of Neonatal Mortality after Multiple Doses of Bovine Surfactant in Low Birth Weight Neonates with Respiratory Distress Syndrome". Pediatrics 88 (1): 19–28. doi:10.1542/peds.88.1.19. PMID 2057268. http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=2057268.
- ↑ Kendig, James W.; Notter, Robert H.; Cox, Christopher; Aschner, Judy L.; Benn, Steven; Bernstein, Richard M.; Hendricks-Munoz, Karen; Maniscalco, William M. et al. (1 November 1988). "Surfactant Replacement Therapy at Birth: Final Analysis of a Clinical Trial and Comparisons With Similar Trials". Pediatrics 82 (5): 756–762. PMID 3054783. http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=3054783.
- ↑ Lewis, Sharon R.; Pritchard, Michael W.; Thomas, Carmel M.; Smith, Andrew F. (July 23, 2019). "Pharmacological agents for adults with acute respiratory distress syndrome". The Cochrane Database of Systematic Reviews 7 (7). doi:10.1002/14651858.CD004477.pub3. ISSN 1469-493X. PMID 31334568.
 |  |
